High-throughput, Multiplexed, Commercialized Ion Channel Drug Screening

Information

  • Research Project
  • 10080356
  • ApplicationId
    10080356
  • Core Project Number
    R43HL154846
  • Full Project Number
    1R43HL154846-01
  • Serial Number
    154846
  • FOA Number
    PA-19-034
  • Sub Project Id
  • Project Start Date
    9/1/2020 - 4 years ago
  • Project End Date
    6/30/2021 - 3 years ago
  • Program Officer Name
    DANTHI, NARASIMHAN
  • Budget Start Date
    9/1/2020 - 4 years ago
  • Budget End Date
    6/30/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/28/2020 - 4 years ago

High-throughput, Multiplexed, Commercialized Ion Channel Drug Screening

Project Summary Ion channels are integral membrane proteins that control the flux of ions through cellular membranes and they are often responsive to voltages and ligands, resulting in an active/open state or inactive/closed state. Furthermore, ion channels are involved nearly all physiological processes, including cell-cell communication, muscle contraction, neuronal firing, osmotic stress responses, etc., and dysfunction of these proteins has been related to several human diseases such as asthma, hypertension, diabetes, some cancers, and congenital heart failure, to name a few examples. Because of their important role in disease and potential as drug targets, there is a great deal of interest in characterizing ion channel response, especially regarding drug interactions. However, there remain very pressing issues regarding the ability to develop target-specific drugs that do not modulate the activity of other (non-target) ion channels. This process is quite difficult as most ion channels that have the potential to bind drug-like molecules remain understudied. During this program, Electronic BioSciences, Inc. (EBS) will develop and demonstrate an automated, multiplexed, fluidic-based system that will allow multiple ion channels and drug targets to be screened simultaneously with state-of-the-art noise-performance/resolution at the single-channel level. A tool such as the one proposed here, capable of broad, high-throughput commercial drug screening (i.e., many ion channels and many drugs), will help expand the pool of information needed to design and characterize new high-affinity/high-specificity drugs for improved patient care.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224493
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:224493\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ELECTRONIC BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    129852864
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921214206
  • Organization District
    UNITED STATES